Vitespen, an investigational cancer vaccine, appears to be beneficial for treating patients with recurrent high-grade glioma

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1667, 2008-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mitoxantrone appears to have beneficial effects in patients with recurrent neuromyelitis optica

By  

Inpharma, Vol. 1, Iss. 1553, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

A melanoma vaccine [`Melacine'] appears to be beneficial in patients with malignant melanoma

By  

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Salvage Hypofractionated Radiotherapy in Combination with Bevacizumab in Patients with Recurrent High Grade Glioma: A Mono-institutional Experience

By  

Clinical Cancer Drugs, Vol. 4, Iss. 2, 2018-01 ,pp. : 145-149

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting ErbB Receptors in High-Grade Glioma

By  

Current Pharmaceutical Design, Vol. 17, Iss. 23, 2011-08 ,pp. : 2468-2487

Bentham Science Publishers

Access to resources Recommend Favorite

Current and future directions for Phase II trials in high-grade glioma

By Alexander Brian M   Lee Eudocia Q   Reardon David A   Wen Patrick Y  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 4, 2013-04 ,pp. : 369-387

Informa Healthcare

Access to resources Recommend Favorite